F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comWanbury Ltd is a fast-growing pharmaceutical company in India known for its strong presence in Active Pharmaceutical Ingredients (APIs), branded formulations, and contract manufacturing. With consistent export demand and improving financial performance, the company has gained attention from retail investors in recent years.
In this example article, we’ll explore Wanbury Ltd share price target from 2025 to 2030, its market performance, and potential investment outlook — using the provided figures.
| Detail | Value |
|---|---|
| Open | ₹242.00 |
| Previous Close | ₹241.15 |
| Day’s High | ₹247.10 |
| Day’s Low | ₹241.00 |
| 52-Week High | ₹329.70 |
| 52-Week Low | ₹154.01 |
| All-Time High | ₹329.70 |
| All-Time Low | ₹10.75 |
| Volume | 15,299 |
| Value (Lacs) | ₹37.73 |
| VWAP | ₹243.32 |
| 20-Day Avg Volume | 109,818 |
| 20-Day Avg Delivery (%) | 52.09 |
| Market Cap (Rs. Cr.) | ₹808 |
| Beta (Volatility) | 1.33 |
| Book Value Per Share | ₹11.83 |
| Face Value | ₹10 |
The company currently trades around ₹242–₹247 levels, with a market capitalization of ₹808 crore. The stock has witnessed volatility, with a beta of 1.33, suggesting it tends to move more than the broader market — often favored by swing and positional traders.
Founded in 1988, Wanbury Ltd operates in the pharmaceutical sector with a focus on formulations, APIs, and nutraceuticals. The company serves both domestic and international markets, especially in Europe and Latin America, with manufacturing facilities that adhere to global quality standards.
In recent years, Wanbury has focused on debt restructuring, operational efficiency, and expanding its export base. Its product portfolio includes pain management, cardiovascular, and antibiotic categories.
Strong API manufacturing capabilities and export base
Diversified product portfolio across therapeutic categories
Efforts towards debt reduction and profitability improvement
Stock volatility offers opportunities for short-term traders
Stable retail participation ensures liquidity
| Investor Type | Holding (%) |
|---|---|
| Retail & Others | 56.08% |
| Promoters | 43.09% |
| Foreign Institutions | 0.82% |
Retail investors hold a majority of the shares, while promoter holding remains strong at over 43%. The limited institutional exposure indicates untapped potential for future re-rating if fundamentals improve.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 250 | 270 |
| 2026 | 280 | 320 |
| 2027 | 330 | 370 |
| 2028 | 380 | 420 |
| 2029 | 425 | 470 |
| 2030 | 480 | 540 |
These targets are illustrative and assume gradual revenue growth, improved debt management, and consistent profitability.
By 2025, Wanbury’s share price may remain stable with minor upward momentum.
Why:
Steady API demand and improved exports
Optimizing operations post-debt restructuring
Short-term volatility driven by trading interest
Investment Advice:
Ideal for short-term traders and cautious investors; wait for quarterly results before long-term entry.
In 2026, the company could see moderate growth as financial restructuring starts reflecting in the bottom line.
Why:
Expanding domestic formulations business
Stronger export realizations
Increased investor participation
Investment Advice:
Hold for medium term; book profits near ₹320 levels if momentum slows.
2027 could mark an important milestone as Wanbury stabilizes margins and builds consistent export order flows.
Why:
Sustained growth in API exports
Improvement in working capital efficiency
Recovery from previous debt pressures
Investment Advice:
Hold for long-term gains; reinvest dividends or returns into further compounding positions.
By 2028, Wanbury could witness improved earnings visibility and a potential re-rating.
Why:
Expanding product pipeline in chronic therapies
Entry into new regulated markets
Better cash flow and balance sheet metrics
Investment Advice:
Good accumulation zone for long-term investors; continue SIP-based entries during market corrections.
If Wanbury sustains growth and profitability, it could attract institutional interest, further strengthening valuation.
Why:
Increased brand visibility in pharma sector
Higher export contribution to total revenues
Better liquidity and investor sentiment
Investment Advice:
Long-term investors can continue to hold; consider partial booking above ₹450 if overbought conditions appear.
By 2030, Wanbury Ltd could emerge as a strong mid-cap pharma player, provided it maintains consistent growth and effective cost control.
Why:
Diversification across APIs and formulations
Improved profitability ratios and return on equity
Industry-wide revaluation of small and mid-cap pharma stocks
Investment Advice:
Good option for long-term portfolios focused on pharma and healthcare growth themes.
Wanbury Ltd is a small-cap pharma stock with high potential but moderate risk. Its operational efficiency, export-led growth, and debt restructuring could support a multi-year turnaround story.
Strong promoter commitment (43.09%)
Focus on niche API exports
Improving financial discipline and balance sheet repair
Moderate dividend potential
High volatility (beta 1.33) may affect short-term investors
Dependence on export orders and regulatory clearances
Competition in API and formulation segments
Limited institutional coverage
Wanbury Ltd presents a promising growth story in the pharmaceutical space, albeit with higher volatility. If the company continues to improve its margins and reduce debt, the stock could witness steady appreciation, potentially reaching between ₹480 and ₹540 by 2030 under favorable conditions.
For long-term investors, Wanbury could serve as a high-risk, high-reward addition within a diversified pharma portfolio. Regular tracking of quarterly results and debt levels is essential.
1. What is the current share price of Wanbury Ltd?
As of November 2025, the stock trades near ₹242–₹247.
2. What is the market capitalization of Wanbury Ltd?
The company’s market cap stands at approximately ₹808 crore.
3. What is Wanbury’s 52-week high and low?
The 52-week high is ₹329.70 and the low is ₹154.01.
4. What is the promoter holding in Wanbury Ltd?
Promoters hold around 43.09% of total shares.
5. Is Wanbury Ltd a small-cap company?
Yes, Wanbury is a small-cap company operating in the pharmaceuticals sector.
6. What is the book value per share of Wanbury Ltd?
Book value per share is ₹11.83.
7. Is Wanbury Ltd a good stock for the long term?
Yes, but only for investors comfortable with high volatility and small-cap risk.
8. What is the stock’s beta?
Beta is 1.33, indicating higher price fluctuations than the market average.
9. What are Wanbury’s key business areas?
APIs, branded formulations, and contract manufacturing for domestic and international markets.
10. What could be the price target for Wanbury Ltd by 2030?
Under favorable conditions, Wanbury Ltd could reach ₹480 – ₹540 by 2030.
Disclaimer: This article is for educational and informational purposes only. It does not constitute financial or investment advice. Investors are advised to perform independent research and consult a registered financial advisor before making investment decisions.
Register & Login